# US 2003/0078427 A1 · Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0078427 A1
- Document ID: US20030078427A1
- Status: Published application
- Kind: A1
- Application number: 10/162,802
- Filed: 2002-06-05
- Published: 2003-04-24
- Earliest claimed: 1997-07-11
- Assignees: Janssen Pharmaceutics, N.V.
- Inventors: Jean-Paul Rene Marie Andre Bosmans; Michel Anna Jozef De Cleyn; Michel Surkyn
- Web page: https://patentgrep.com/patent/US20030078427A1

## CPC

- C07D 211/42: attached in position 3 or 5
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/10: Laxatives
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 211/44: attached in position 4
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present invention of compounds of formula (I) 1 a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R1 is C1-6alkyloxy, C2-6alkenyloxy or C2-6alkynyl-oxy; R2 is hydrogen, C1-6alkyl C1-6alkyloxy; R3 is hydrogen or halo; R4 is hydrogen or C1-6alkyl; R5 is hydrogen or C1-6alkyl; L is C3-6cycloalkyl, C5-6cycloalkanone, C2-6alkenyl, or L is a radical of formula-Alk-R6—, Alk-X—R7, —Alk-Y—C(═O)—R9, or —Alk-Y—C(═O)—NR11R12 wherein each Alk is C1-12alkanediyl; and R6 is hydrogen, cyano, C1-6alkylsulfonylamino, C3-6cycloalkyl, C5-6cyclo-alkanone, or a heterocyclic ringsystem; R7 is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C3-6cycloalkyl, or a heterocyclic ringsystem; X is O, S, SO2 or NR8; said R8 being hydrogen or C1-6alkyl; R9 is hydrogen, C1-6alkyl, C3-6cycloalkyl, C1-6alkyloxy or hydroxy; Y is NR10 or a direct bond; said R10 being hydrogen, or C1-6alkyl; R11 and R12 each independently are hydrogen, C1-6alkyl, C3-6cycloalkyl, or R11 and R12 combined with the nitrogen atom may form an optionally substituted pyrrolidinyl, piperidinyl, piperazinyl or 4-morpholinyl ring. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.

## Claims

### Claim 1

A compound of formula (I)
86
a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid or base addition salt thereof, wherein
R1 is C1-6alkyloxy, C2-6alkenyloxy or C2-6alkynyloxy;
R2 is hydrogen, C1-6alkyl or C1-6alkyloxy;
R3 is hydrogen or halo;
R4 is hydrogen or C1-6alkyl;
R5 is hydrogen or C1-6alkyl;
L is C3-6cycloalkyl, C5-6cycloalkanone, or C2-6alkenyl, or L is a radical of formula
—Alk-R6 (b-1),—Alk-X—R7 (b-2),—Alk-Y—C(═O)—R9 (b-3),
or
—Alk-Y—C(═O)—NR11R12 (b-4),
wherein each Alk is C1-12alkanediyl; and
R6 is hydrogen, hydroxy, cyano, C1-6alkylsulfonylamino, C3-6cycloalkyl, C5-6cycloalkanone, or Het1;
R7 is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C3-6cycloalkyl, or Het2;
X is O, S, SO2 or NR8; said R8 being hydrogen or C1-6alkyl;
R9 is hydrogen, C1-6alkyl, C3-6cycloalkyl, C1-6alkyloxy or hydroxy;
Y is NR10 or a direct bond; said R10 being hydrogen or C1-6alkyl;
R11 and R12 each independently are hydrogen, C1-6alkyl, C3-6cycloalkyl, or R11 and R12 combined with the nitrogen atom bearing R11 and R12 may form a pyrrolidinyl or piperidinyl ring both being optionally substituted with C1-6alkyl, amino or mono or di(C1-6alkyl)amino, or said R11 and R12 combined with the nitrogen bearing R11 and R12 may form a piperazinyl or 4-morpholinyl radical both being optionally substituted with C1-6alkyl; and Het1 and Het2 each independently are selected from furan; furan substituted with C1-6alkyl or halo; tetrahydrofuran; a tetrahydrofuran substituted with C1-6alkyl; a dioxolane; a dioxolane substituted with C1-6alkyl, a dioxane; a dioxane substituted with C1-6alkyl; tetrahydropyran; a tetrahydropyran substituted with C1-6alkyl; pyrrolidinyl; pyrrolidinyl substituted with one or two substituents each independently selected from halo, hydroxy, cyano, or C1-6alkyl; pyridinyl; pyridinyl substituted with one or two substituents each independently selected from halo, hydroxy, cyano, C1-6alkyl; pyrimidinyl; pyrimidinyl substituted with one or two substituents each independently selected from halo, hydroxy, cyano, C1-6alkyl, C1-6alkyloxy, amino and mono and di(C1-6alkyl)amino; pyridazinyl; pyridazinyl substituted with one or two substituents each independently selected from hydroxy, C1-6alkyloxy, C1-6alkyl or halo; pyrazinyl; pyrazinyl substituted with one ore two substituents each independently selected from halo, hydroxy, cyano, C1-6alkyl, C1-6alkyloxy, amino, mono- and di(C1-6alkyl)amino and C1-6alkyloxycarbonyl;
Het1 can also be a radical of formula
87
Het1 and Het2 each independently can also be selected from the radicals of formula
88
R13 and R14 each independently are hydrogen or C1-4alkyl.

### Claim 2 (depends on 1)

A compound as claimed in claim 1 wherein R1 is C1-4alkyloxy and R2 is hydrogen, C1-4alkyl or C1-4alkyloxy.

### Claim 3 (depends on 1)

A compound as claimed in claim 1 wherein R1 is C1-4alkyloxy, and R2 is C1-4alkyl or C1-4alkyloxy.

### Claim 4 (depends on 1, 2, 3)

A compound as claimed in any of claims 1 to 3 wherein the —OR4 radical is situated at the 3-position of the central piperidine moiety having the trans configuration.

### Claim 5 (depends on 1, 2, 3)

A compound as claimed in any of claims 1 to 3 wherein the —OR4 radical is situated at the 4-position of the central piperidine moiety.

### Claim 6 (depends on 1, 2, 3, 4)

A compound as claimed in any of claims 1 to 4 wherein L is C3-6cycloalkyl or C2-6alkenyl; or L is a radical of formula (b-1), wherein each Alk is C1-6alkanediyl, and R6 is hydrogen, hydroxy, cyano, amino, C1-6alkylsulfonylamino, C3-6cycloalkyl or Het1, wherein Het1 is tetrahydrofuran; dioxolane; dioxolane substituted with C1-6alkyl; tetrahydropyran; pyridazinyl substituted with one or more substituents selected from hydroxy, halo and C1-6alkyl; or a radical of formula (c-1), (c-3) or (c-4) wherein R13 is C1-4alkyl; or L is a radical of formula (b-2), wherein Alk is C1-6alkanediyl, X is O, and R7 is C1-6alkyl or hydroxyC1-6alkyl; or L is a radical of formula (b-2), wherein Alk is C1-6alkanediyl, R7 is Het2 wherein Het2 is pyrazinyl substituted with C1-6alkyl, and X is NR8 wherein R8 is hydrogen or C1-6alkyl; or L is a radical of formula (b-3) wherein Y is a direct bond, and R9 is C1-6alkyl, hydroxy or C1-6alkyloxy; or L is a radical of formula (b-4) wherein Y is a direct bond, and R11 and R12 are C1-6alkyl, or R11 and R12 combined with the nitrogen atom bearing R11 and R12 form pyrrolidinyl.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound according to any of claims 1 to 6.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A process for preparing a pharmaceutical composition according to claim 7 wherein a therapeutically active amount of a compound according to any of claims 1 to 6 is intimately mixed with a pharmaceutically acceptable carrier.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

A compound according to any of claims 1 to 6 for use as a medicine.

### Claim 10 (depends on 1)

A compound of formula (III)
89
a pharmaceutically acceptable acid addition salt thereof or a stereochemically isomeric form thereof, wherein R1, R2, R3, R4 and R5 are as defined in claim 1 for compounds of formula (I).

### Claim 11 (depends on 1)

A compound of formula (V) wherein L, R4 and R5 are as defined in claim 1.
90

### Claim 12

A compound of formula (VI) wherein R1 is methoxy, R2 is methyl and R3 is chloro.
91

### Claim 13 (depends on 1)

A compound of formula (IX) wherein R4 and R5 are as defined in claim 1, and R15 and R16 are each independently selected from hydrogen or a protective group PG.
92

### Claim 14 (depends on 1)

A process for preparing a compound of formula (I) wherein
a) an intermediate of formula (II) is N-alkylated with an intermediate of formula (III) in a reaction-inert solvent and, optionally in the presence of a suitable base,
93
b) an appropriate ketone or aldehyde intermediate of formula L′═O (IV), said L′═O being a compound of formula L—H, wherein two geminal hydrogen atoms in the C1-12 alkanediyl moiety are replaced by ═O, is reacted with an intermediate of formula (III);
94
c) an intermediate of formula (V) is reacted with an carboxylic acid derivative of formula (VI) or a reactive functional derivative thereof;
95
d) an intermediate of formula (VII), wherein X is bromo or iodo, is carbonylated in the presence of an intermediate of formula (V) in a reaction-inert solvent in the presence of a suitable catalyst and a tertiary amine, and at a temperature ranging between room temperature and the reflux temperature of the reaction mixture;
96
wherein in the above reaction schemes the radicals L, R1, R2, R3, R4 and R5 are as defined in claim 1 and W is an appropriate leaving group;
e) or, compounds of formula (I) are converted into each other following art-known transformation reactions; or if desired; a compound of formula (I) is converted into a pharmaceutically acceptable acid addition salt, or conversely, an acid addition salt of a compound of formula (I) is converted into a free base form with alkali; and, if desired, preparing stereochemically isomeric forms thereof.

### Claim 15 (depends on 1)

A process for preparing a compound of formula (III) wherein
a) an intermediate of formula (VIII), wherein PG is an appropriate protective group, is reacted with an acid of formula (VI), or an appropriate reactive functional derivative thereof, in a reaction-inert solvent and subsequent deprotection of the protecting group PG yielding compounds of formula (III);
97
wherein in the above reaction schemes the radicals L, R1, R2, R3, R4 and R5 are as defined in claim 1 and W is an appropriate leaving group;
b) or, compounds of formula (III) are converted into each other following art-known transformation reactions; or if desired; a compound of formula (III) is converted into an acid addition salt, or conversely, an acid addition salt of a compound of formula (III) is converted into a free base form with alkali; and, if desired, preparing stereochemically isomeric forms thereof.
